Department of Orthopaedic Surgery, Inje University College of Medicine, Seoul Paik Hospital, Seoul, South Korea.
Department of Orthopaedic Surgery, Center for Metabolism and Obesity Research, Johns Hopkins University School of Medicine, Baltimore, MD.
J Arthroplasty. 2019 Jan;34(1):163-168.e1. doi: 10.1016/j.arth.2018.09.005. Epub 2018 Sep 22.
Glucocorticoid usage, a leading cause of osteonecrosis of the femoral head (ONFH), and its prevalence was reported in 25%-50% of non-traumatic ONFH patients. Nevertheless, there have been no unified criteria to classify glucocorticoid-associated ONFH (GA-ONFH). In 2015, the Association Research Circulation Osseous addressed the issue of developing a classification scheme.
In June 2017, a task force was set up to conduct a Delphi survey concerning ONFH. The task force invited 28 experts in osteonecrosis/bone circulation from 8 countries. Each round of the Delphi survey consists of questionnaires, analysis of replies, and feedback reports to the panel. After 3 rounds of the survey, the panel reached a consensus on the classification criteria. The response rates were 100% (Round 1), 96% (Round 2), and 100% (Round 3), respectively.
The consensus on the classification criteria of GA-ONFH included the following: (1) patients should have a history of glucocorticoid use >2 g of prednisolone or its equivalent within a 3-month period; (2) osteonecrosis should be diagnosed within 2 years after glucocorticoid usage, and (3) patients should not have other risk factor(s) besides glucocorticoids.
Association Research Circulation Osseous established classification criteria to standardize clinical studies concerning GA-ONFH.
糖皮质激素的使用是导致股骨头坏死(ONFH)的主要原因之一,其在非创伤性 ONFH 患者中的患病率为 25%-50%。然而,目前还没有统一的标准来对糖皮质激素相关性 ONFH(GA-ONFH)进行分类。2015 年,骨循环研究协会提出了制定分类方案的问题。
2017 年 6 月,成立了一个工作组,就 ONFH 问题进行了 Delphi 调查。该工作组邀请了来自 8 个国家的 28 名骨坏死/骨循环专家。Delphi 调查的每一轮都包括问卷、回复分析和向专家组反馈报告。经过 3 轮调查,专家组就分类标准达成了共识。各轮的回复率分别为 100%(第 1 轮)、96%(第 2 轮)和 100%(第 3 轮)。
GA-ONFH 分类标准的共识包括:(1)患者应具有糖皮质激素使用史,即 3 个月内使用泼尼松龙>2g 或其等效药物;(2)糖皮质激素使用后 2 年内诊断为骨坏死;(3)患者除糖皮质激素外无其他危险因素。
骨循环研究协会制定了分类标准,以规范 GA-ONFH 的临床研究。